94 Results for "

Neuronal injury

" in MedChemExpress (MCE) Product Catalog:
Products (94)

94 Results for "Neuronal injury" in MCE Product Catalog:

102
102 Publications Verification
Cat. No.: HY-P1061
CAS No.: 867021-83-8
Target:  

STAT Amyloid-β

Research Areas:  

Neurological Disease

Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury
loading...
    loading...
102
102 Publications Verification
Cat. No.: HY-P1061A
CAS No.: 2803948-60-7
Target:  

STAT Amyloid-β Apoptosis

Research Areas:  

Neurological Disease

Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro . Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease . Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury .
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-100403
CAS No.: 298690-60-5
Purity:  99.67%
Target:  

mGluR

Research Areas:  

Cancer

Ro 67-7476 is a potent positive allosteric modulator of mGluR1 and potentiates glutamate-induced calcium release in HEK293 cells expressing rat mGluR1a with an EC50 of 60.1 nM . Ro 67-7476 is a potent P-ERK1/2 agonist and activates ERK1/2 phosphorylation in the absence of exogenously added glutamate (EC50=163.3 nM) .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-B0331
CAS No.: 75847-73-3
Synonyms: MK-421
Enalapril (MK-421) is an orally active angiotensin-converting enzyme inhibitor. Enalapril blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-B0331A
CAS No.: 76095-16-4
Synonyms: MK-421 maleate
Enalapril maleate (MK-421 maleate) is an orally active angiotensin-converting enzyme inhibitor. Enalapril maleate blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril maleate inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril maleate attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril maleate reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril maleate is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-N0762
CAS No.: 31524-62-6
Isobavachin is an orally active, blood-brain barrier-penetrating prenylated flavonoid present in Psoralea corylifolia. Isobavachin inhibits human CYP2B6, CYP2C9, CYP2C19, UGT1A1, UGT1A9, and UGT2B7. Isobavachin suppresses MAPK activation, NF-κB nuclear translocation, overexpression of iNOS/COX-2, FcεRI-mediated signaling pathways, and RANKL-induced osteoclastogenesis. Isobavachin induces autophagy, cytotoxicity, neuronal differentiation, and NRF2 activation; it alleviates oxidative damage, inflammatory responses, apoptosis, iron accumulation, mitochondrial biogenesis, and mast cell degranulation. Isobavachin is applicable to research related to liver injury, inflammatory diseases, osteoporosis, liver cancer, prostate cancer, glioma, periodontitis-induced bone loss, and Alzheimer's disease .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-138646
CAS No.: 86828-69-5
Synonyms: Poly(dA:dT) sodium
Research Areas:  

Inflammation/Immunology

Poly(deoxyadenylic-thymidylic) acid (Poly(dA:dT)) sodium is a double-stranded DNA stimulant. Poly(deoxyadenylic-thymidylic) acid sodium is recognized by the intracellular DNA sensor DDX41 and activates the innate immune pathway via the adaptor protein STING, inducing the production of cytokines such as type I interferons. Poly(deoxyadenylic-thymidylic) acid sodium also serves as an in vitro transcription template for free RNA polymerase .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15322
CAS No.: 1370261-96-3
Purity:  99.38%
Synonyms: P505-15; PRT-2607; BIIB-057
Target:  

Syk Apoptosis Caspase

Research Areas:  

Inflammation/Immunology Cancer

PRT062607 (P505-15; PRT-2607) is an orally active ATP-competitive Syk inhibitor with an IC50 value of 1 nM, and exhibits at least 80-fold selectivity over other kinases. PRT062607 blocks B cell antigen receptor-mediated activation, Fcε receptor 1-mediated basophil degranulation and microglial phagocytosis, and induces caspase-dependent apoptosis and microglial death. PRT062607 inhibits tumor growth and peripheral nerve injury-induced mechanical allodynia, and prevents neuronal loss. PRT062607 can be used in research related to rheumatoid arthritis, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, neurodegenerative diseases and neuropathic pain .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-114869
CAS No.: 129075-73-6
Purity:  99.68%
Target:  

PARP

Research Areas:  

Neurological Disease Cancer

DPQ is a selective PARP-1 inhibitor that blocks PARP-1-mediated DNA damage repair and NAD +/ATP consumption, thereby inhibiting excessive inflammatory responses. DPQ inhibits NF-κB pathway activation, reduces the expression of pro-inflammatory factors (such as TNF-α, IL-6) and oxidative stress. DPQ can be used in inflammation-related studies of acute lung injury, myocardial infarction, and neurodegenerative diseases .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P3400
CAS No.: 887255-16-5
Synonyms: LQVTDSGLYRCVIYHPP
Target:  

Inhibitory Antibodies

Research Areas:  

Neurological Disease

LP17 (LQVTDSGLYRCVIYHPP) is a BBB-penetrable triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LP17 substantially alleviates ischemia-induced infarction and neuronal injury. LP17 can get access into brain and block TREM-1 .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-128879A
CAS No.: 1281681-33-1
Purity:  98.01%
VP3.15 dihydrobromide is a highly potent, orally bioavailable, and CNS-penetrant PDE7-GSK3 dual inhibitor, with IC50 values of 1.59 μM and 0.88 μM against PDE7 and GSK3, respectively . VP3.15 dihydrobromide elevates intracellular cAMP levels, suppresses immune responses, enhances remyelination, limits excessive tau phosphorylation, and alleviates neuroinflammation and neuronal loss. VP3.15 dihydrobromide promotes oligodendrocyte precursor cell differentiation, improves in vivo remyelination, inhibits autoimmune encephalomyelitis, and mitigates germinal matrix-intraventricular hemorrhage-related brain injury, cerebral atrophy, ventricular enlargement, and cognitive impairment. VP3.15 dihydrobromide can be used in research related to multiple sclerosis and germinal matrix-intraventricular hemorrhage .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-103435
CAS No.: 858134-23-3
Purity:  99.90%
Synonyms: Terrestrin A
Vialinin A (Terrestrin A) is a p-terphenyl compound that can be derived from a Chinese edible mushroom. Vialinin A is an inhibitor of ubiquitin-specific peptidase 4 (USP4) and has anti-inflammatory and antioxidant properties. Vialinin A can alleviate cerebral ischaemia-reperfusion injury-induced neurological deficits and neuronal apoptosis. Vialinin A promotes activation of Keap1-Nrf2-ARE signaling pathway and increases the protein degradation of Keap1. Vialinin A possesses various pharmacological activities in cancer, Kawasaki disease, asthma, and pathological scarring. Vialinin A is a potent inhibitor of TNF-α, USP4, USP5, and sentrin/SUMO-specific protease 1 (SENP1). Vialinin A can be studied in reseach for autoimmune diseases, cancer and ischaemic stroke .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P3400A
Synonyms: LQVTDSGLYRCVIYHPP TFA
Target:  

Inhibitory Antibodies

Research Areas:  

Neurological Disease

LP17 (LQVTDSGLYRCVIYHPP) TFA is a BBB-penetrable triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LP17 TFA substantially alleviates ischemia-induced infarction and neuronal injury. LP17 TFA can get access into brain and block TREM-1 .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-B0985
CAS No.: 136-40-3
Target:  

TRP Channel

Research Areas:  

Neurological Disease

Phenazopyridine hydrochlorideis a competitive SARM1 inhibitor, with IC50 145 μM. Phenazopyridine hydrochlorideis a TRPM8 antagonist. Phenazopyridine hydrochloride has a local anesthetic/analgesic effect. Phenazopyridine hydrochlorideis used to relieve painful symptoms of conditions such as cystitis and urethritis. Phenazopyridine hydrochloridecan promote neuronal differentiation and can also be used in the study of traumatic brain injury, peripheral neuropathy and neurodegenerative diseases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-15416
CAS No.: 18711-16-5
Purity:  99.09%
NS309 is a potent and selective activator of the Ca 2+-activated SK/IK potassium channels, but displays no activity at BK channels .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12119
CAS No.: 210354-22-6
Purity:  ≥98.0%
Target:  

NO Synthase

GW274150 is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 also displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 exerts a protective role in an acute model of lung injury inflammation .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0541
CAS No.: 69884-00-0
Synonyms: Ginsenoside A1
Pseudoginsenoside F11 is an orally active neuroprotective agent. Pseudoginsenoside F11 reduces the expression of β-amyloid precursor protein, inhibits the production of 1-40, downregulates the expression of JNK2, p53 and activated Caspase 3, and restores the activities of SOD and Glutathione peroxidase. Pseudoginsenoside F11 inhibits the excessive activation of μ-Calpain and restores the level of neuronal Nitric oxide synthase. Pseudoginsenoside F11 reduces infarct volume, alleviates cerebral edema, decreases neuronal loss, improves neurological deficits and enhances long-term functional outcomes in transient cerebral ischemia models. Pseudoginsenoside F11 antagonizes Methamphetamine-induced behavioral deficits, dopamine level reduction and neurotoxicity without altering the baseline behaviors of normal mice. Pseudoginsenoside F11 can be used in studies related to Alzheimer's disease, transient cerebral ischemic injury and Methamphetamine-induced neurotoxicity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N11849
CAS No.: 135248-05-4
Moracin N is a benzofuran compound. At low concentrations, Moracin N activates the Keap1/Nrf2 pathway, downregulates the expression of FTH1 and ACSL4, enhances glutathione synthesis, and inhibits neuronal ferroptosis. At high concentrations, Moracin N induces ROS accumulation, activates mitochondrial apoptosis, and triggers autophagy-mediated cell death by inhibiting the AKT/mTOR pathway. Moracin N can be used in research related to non-small cell lung cancer, hepatocellular carcinoma and ischemic brain injury .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12119A
CAS No.: 438542-15-5
Purity:  99.85%
Target:  

NO Synthase

GW274150 phosphate is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 phosphate displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 phosphate exerts a protective role in an acute model of lung injury inflammation .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-101318
CAS No.: 72786-10-8
Purity:  98.0%
Synonyms: β-FNA hydrochloride
β-Funaltrexamine (β-FNA) hydrochloride is a blood-brain barrier-permeable, selective and irreversible μ-opioid receptor antagonist with immunomodulatory, anti-inflammatory and neuroprotective activities. β-Funaltrexamine hydrochloride inhibits p38 MAPK and TLR4 signaling by blocking μ-opioid receptors, and reduces the transcriptional activities of NF-κB, AP-1, CREB and Stat. Furthermore, β-Funaltrexamine hydrochloride inhibits iNOS activation and pro-inflammatory microglial polarization, converting microglia to an anti-inflammatory phenotype, thereby downregulating neuroinflammation and ameliorating neuronal degeneration. β-Funaltrexamine hydrochloride is widely applicable to research related to stroke, cerebral ischemia/reperfusion injury and neurodegenerative diseases .
loading...
    loading...